We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Azitra Inc is an early-stage clinical biopharmaceutical company. The Company is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library ... Azitra Inc is an early-stage clinical biopharmaceutical company. The Company is focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products that can be applied topically to treat diseases of the skin. Its platform includes a microbial library comprised of approximately 1,500 bacterial strains that can be screened for therapeutic characteristics. The platform is augmented by artificial intelligence and machine learning technology that analyzes, predicts and helps screen its library of strains for drug-like molecules. Its product ATR-12 is a genetically modified strain of S. epidermidis for treating the orphan disease, Netherton syndrome, a chronic and fatal disease of the skin. Its product ATR-04 is a genetically modified strain of S. epidermidis for treating the papulopustular rash. Its product ATR-01 is a human filaggrin protein for treating ichthyosis vulgaris, a chronic, xerotic (abnormally dry), and scaly skin disease. Show more
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the U.S. Food and Drug...
Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it announced today that Travis Whitfill, COO, will present an overview of the Company at the H.C. Wainwright...
Azitra, Inc. (NYSE American: AZTR), a precision dermatology company, announced that it has initiated dosing the first patient in its Phase 1b clinical trial evaluating ATR-12 for the treatment of...
New investigational new drug (IND) application cleared to proceed by the US FDA for a Phase 1/2 clinical study of ATR-04 for moderate to severe EGFR inhibitor (βEGFRiβ) associated dermal...
Azitra, Inc. (NYSE American: AZTR), a precision dermatology company announced that it has successfully screened the first patient in its Phase 1b clinical trial evaluating ATR-12 for the...
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the three...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.024 | 4.28571428571 | 0.56 | 0.667 | 0.535 | 567425 | 0.59332759 | CS |
4 | -0.12 | -17.0454545455 | 0.704 | 0.76 | 0.52 | 520665 | 0.66479651 | CS |
12 | -3.139 | -84.3137254902 | 3.723 | 12 | 0.492 | 3220714 | 2.57560176 | CS |
26 | -6.445 | -91.6915635225 | 7.029 | 12 | 0.492 | 2430201 | 3.90205149 | CS |
52 | -53.116 | -98.9124767225 | 53.7 | 68.4 | 0.492 | 1324389 | 4.44018446 | CS |
156 | -127.216 | -99.5430359937 | 127.8 | 155.4 | 0.492 | 1060845 | 5.03656688 | CS |
260 | -127.216 | -99.5430359937 | 127.8 | 155.4 | 0.492 | 1060845 | 5.03656688 | CS |
Symbol | Price | Vol. |
---|---|---|
SGNSigning Day Sports Inc | $ 0.514 (295.69%) | 485.33M |
SOXLDirexion Daily Semiconductor Bull 3X Shares | $ 36.0219 (15.68%) | 77.77M |
SOXSDirexion Daily Semiconductor Bear 3X Shares New | $ 21.035 (-15.59%) | 61.69M |
SPXSDirexion Daily S&P 500 Bear 3X Shares New | $ 6.8193 (-5.68%) | 33.96M |
SPYSPDR S&P 500 | $ 571.935 (1.88%) | 33.69M |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions